Purification and Characterization of Prostate-Specific Antigen (PSA) Complexed to a1 -Antichymotrypsin: Potential Reference Material for International Standardization of PSA Immunoassays Zuxiong Chen, Anthony Prestiglacomo, and Thomas A. Stamey ' We describe for the first time a protocol to purify to apparent homogeneity an in vitro-prepared complex of prostate-specific antigen (PSA) and a -antichymotrypsin (ACT) by using a combination of gel filtration and ionexchange chromatography. The purity of the PSA-ACT complex was confirmed by gel electrophoresis and Western blot. The PSA-ACT complex was stable in the pH range 6.0 to 7.8; it was also stable in various matrices, temperatures, and high concentrations of salt. Purification of the PSA-ACT complex was highly reproducible.
An absorptivity of 0.99 L X g1 X cm1 at 280 nm was assigned to the PSA-ACT complex, based on amino acid analysis. Because PSA and ACT bind in a 1:1 molar ratio, we determined the molecular mass of the PSA-ACT complex as the mass encoded by the cDNA of ACT (plus 26% carbohydrate) plus the molecular mass of PSA (28 430 Da), which totals 89 280 Da. Using this material, we made two common calibrators, one of 100% PSA-ACT complex and one of 90% PSA-ACT complex plus 10% free PSA by volume (90:10 calibrator). Substitution of these calibrators for the manufacturers' calibrators in nine commercial immunoassays substantially reduced differences between immunoassays, especially for serum PSA values between 4 and 10 g/L. The 90:10 calibrator is recommended as a universal calibrator for international standardization of PSA immunoassays. results of monoclonal and polyclonal assays, which differ in how they recognize the free fraction of PSA in the serum (7). We have shown by gel filtration studies that the difference between these assays is much less when the complexed form of PSA is measured in the serum (7). This strongly suggests that, if the calibrators used were predominantly composed of the complexed form of PSA, these differences between immunoassays would largely disappear. In the present study, we prepared in vitro a PSA-ACT complex, purified it, and used it to prepare new assay calibrators, both 100% PSA-ACT and a 90:10 (by PSA wt.) mixture of complex to free PSA. We then tested the calibrators in four Food and Drug Administration (FDA)-approved assays and five other internationally marketed immunoassays for PSA.
Materials and Methods Materials
followed the procedures of Stanford's Institutional Review Board in using human sera for these studies.
Preparation of PSA-ACT Complex
We incubated at 37 #{176}C for 2 h 2.5 mg of PSA in 20 mmol/L phosphate-buffered saline (PBS), pH 7.4, with 10 mg of ACT in 20 mmol/L Tris-HC1 (pH 7.4) containing 0.2 mol/L NaC1; the molar ratio of PSA to ACT was 1:2. The reaction mixture was then concentrated to 0.8 mL by ultraffitration (Amicon PM 10 membrane; Amicon, Beverly, MA). The concentrated reaction mixture (0.8 mL) was applied to a Sephacryl S-200 column (1.5 X 92 cm), which had been equilibrated with 10 mmol/L sodium acetate buffer (pH 5.6) containing 0.15 mol/L sodium chloride. Fractions (0.7 mL) were collected at a flow rate of 0.1 mllmin.
Two protein peaks were separated by measuring absorbance at 280 mu; the first asymmetrical peak contained PSA-ACT complex plus excess ACT, whereas the second peak represented excess PSA that was unable to form a complex with ACT. About 20 fractions in the first peak were combined, concentrated to 1 mL by ultrafiltration as described above, and diafiltrated against 10 mL of 10 minol/L sodium acetate buffer (pH 5.6). This concentrated sample (1 mL) from gel filtration chromatography was then applied to a column of CM-cellulose (1 X 18 cm) equilibrated with 10 mmol/L sodium acetate buffer (pH 5.6) and washed with the same buffer at a flow rate of 0.15 mL/min. The excess ACT at pH 5.6 was not bound to the CM-cellulose and passed through the column.
The column was then eluted with a linear gradient of sodium chloride, from 0 to 1 mol/L in the same buffer. A single peak, PSA-ACT complex, was eluted at -0.3 mol/L sodium chloride. Constructionof CalibratorsContainingPSA-ACTComplex Tandem#{174}-R, the TOSOH AIA#{174}-600, the Abbott IMx#{174}, and the Ciba-Corning ACSThI:180_according to the instructions of the manufacturers. (Fig. 1, lanes 7-9) . The time course of formation of PSA-ACT complex corresponds with the time course of the inhibition of enzymatic activity of PSA by ACT (Fig. 1, right) . At 30 mm, the inhibition of enzymatic activity of PSA has almost reached its nadir. Therefore, 2 h of incubation of PSA with ACT is more than sufficient to form the PSA-ACT complex. 
Results

Formation of PSA-ACT Complex
SDS-PAGE.
Purification.
Gel filtration chromatography gives a highly reproducible and predictable result (Fig. 2) , yielding two protein peaks. The PSA-ACT complex and excess ACT elute in the asymmetrical, high-molecularmass peak (90 kfla), whereas the excess PSA (unable to complex to ACT) elutes in a low-molecular-mass peak (30 kDa). Ion-exchange chromatography on CM-cellulose is useful as a final purification step for the PSA-ACT complex because it separates the PSA-ACT complex from excess ACT successfully.
The excess ACT passes through the CM-cellulose column, whereas the PSA-ACT complex binds to it and is eluted with a linear gradient of NaCl in the same buffer (Fig. 3) . 
CM-cellulose.
The concentrated 90-kOa peak from a Sephacryl S-200 column was applied to a CM-cellulose column (1 x 18 cm) equilibrated with 10 mmol/L sodium acetate buffer (pH 5.6) at a flow rate of 0.15 mL/min, after which the column was washed with the same buffer until A2acreached the baseline. Then, a linear gradient of NaCIfrom 0 to 1 moVL in the same buffer was applied, and 6-mE. fractions were collected. (Fig. 6, top) .
Amino-terminal sequence analysis. Although SDS-PAGE of the purified PSA-ACT complex without boiling gave a single band at 84 kDa (Fig. 6, top, lanes 2-9) , boiling the complex with sample buffer before electrophoresis produced a smear below the major band in SDS-PAGE (Fig. 6, bottom, lanes 2-9) . Amino-terminal sequences were determined for the top band (90 kDa)
94_
u__. and bottom band (8 kDa) seen after electrophoresis (Fig. 4, left panel, lane 8, and Fig. 6, lower panel, (Top) Purified PSA-ACT complex was incubated with sample buffer in nonreducing conditions at room temperature for 10 mm before electrophoresis. Lane 1, molecular mass markers (as in Fig. 4, left) ; lanes 2-9, 6 pg of purified PSA-ACTcomplex. Mean values (all lots, duplicate) of amino acid composition from amino acid analysis were compared with the amino acid composition of PSA-ACT complex calculated on the basis of 614 amino acid residues per mole of PSA-ACT complex. Ten tryptophan and 11 cystemne residues were not included in the analysis.Underlined amino acids were chosen as reference amino acids for calculating the absorptivity. Da for PSA (15), we arrived at a calculated molecular mass for the PSA-ACT complex of 89 280 Da, which we used throughout this study.
Absorptivity.
The absorptivity of the PSA-ACT complex was determined on the basis of the amino acid analysis of 12 different lots of the purified PSA-ACT complex. Nine amino acids were chosen as reference amino acids for quantitation:
Asx, Thr, GIx, Pro, Gly, Ala, Leu, Phe, and Lys. These amino acids represented 65.8% (418 of 635) of the total residues of the consensus cDNA sequence and had the closest amino acid composition to that of the consensus sequence. (Table 3) .
Stability.
The PSA-ACT complex in 10 mmol/L sodium acetate buffer, pH 5.6, containing 0.25 mol/L 
either SDS-PAGE or Western blot (data not shown).
When the PSA-ACT complex was placed in human female serum, goat serum, or PBS buffer containing 10 or 60 g/L BSA (pH 7.4), the immunoreactivity of purified PSA-ACT complex at 4#{176}C was essentially unchanged for at least a month when measured by four FDA-approved kits supplied by Hybritech, TOSOH, Abbott, and Ciba-Corning (data not shown). In the absence of an inimunoassay for free PSA in serum in the US, the dissociation of free PSA from the PSA-ACT complex can be estimated by using a highly equimolar assay (i.e., detects free and complexed PSA with equal affinity) like the TOSOH, in combination with a highly nonequimolar assay whose signal strongly favors free PSA (the Ciba-Corning ACS or Abbott IMx assay). (See the next section for discussion of test samples with 10-30% free PSA.) Thermal stability studies showed that the complex was stable at 37 #{176}C in female serum for at least 8 h (data not shown). Varying the pH from 5.6 to 8.5 at 4 #{176}C for 1 week produced no change in the immunoreactivity of the complex as measured by TOSOH and Ciba-Corning assays (Fig. 8) . The complex was also stable in 10 g/L BSA in PBS (pH 7.4) when subjected to 20 freeze/thaw cycles at -20 #{176}C. When the PSA-ACT complex was lyophilized, >95% of the immunoreactivity was recovered upon reconstitution with water after 30 days of storage at -20 #{176}C (Table 4) , regardless of which matrix was used. Further stability studies are under way and will be tested at 45 #{176}C and 56 #{176}C in both the lyophilized and nonlyophilized state. We also used the 90:10 PSA-ACT calibrator to compare results for preoperative sera from 40 radical prostatectomy patients by the four assays with results for sera from 37 patients with biopsy-proven benign prostatic hyperplasia (BPH). As shown in Table 5 , the regression slopes against TOSOH ranged from 0.99 to 1.01 for the cancer patients (left panels) and from 1.02 to 1.06 for the 37 sera from BPH patients (right panels).
Immunoreactivity
CIba-Coming
To analyze this relationship between the various assays, we used a log-log plot of the regression. As shown in Fig. 9 and Table 5 , the calculated intercept is small and insignificant in all the regression plots. Moreover, using the 90% PSA-ACT complex plus 10% free PSA as the common calibrator gives essentially identical slopes for results for the 95 random sera, the 40 cancer sera, and the 37 BPH sera across all three assays. The identity between the Hybritech Tandem-R assay and the Ciba-Corning ACS assay when using the 90:10 calibrator is especially significant in view of the inherent differences between those two FDA-approved assays. to ACT at all volumes of prostate cancer, whether treated or untreated and regardless of the zonal site of origin of the cancer within the prostate gland (7) .The basic conclusion from that meeting was that major differences between currently available immunoassays for PSA would largely disappear if the calibrators reflected the complexed form of PSA in the serum rather than the free uncomplexed form that is
Discussion
